STAT3 and non-small cell lung carcinoma: Meanwhile, treatment of tumor-bearing mice with the STAT3 inhibitor LL1 sensitizes resistant A549 NSCLC tumors to gefitinib and leads to a synergistic anti-tumor response [264,265].